MECHANISM OF ACTIION^†

Lifitegrast, the active ingredient in XIIDRA^®, blocks the interaction of Intercellular Adhesion Molecule-1 (ICAM-1) and Lymphocyte Function-associated Antigen-1 (LFA-1), which plays a role in the inflammation behind Dry Eye Disease.¹

By blocking the interaction between LFA-1 and ICAM-1, XIIDRA^® may disrupt T-cell migration and activation, which promote the release of cytokines that sustain inflammation. In vitro studies demonstrated that XIIDRA^® may inhibit T-cell adhesion to ICAM-1 and may inhibit the secretion of key inflammatory cytokines.

The exact mechanism of action of lifitegrast in Dry Eye Disease is not known.

^†Clinical significance is unknown